Differentiated thyroid carcinoma (DTC) appears with an incidence of approximately three out of 100 000 and ranks 14th among the major malignancies ([Mazzaferri, 2000](#bib22){ref-type="other"}). In Europe and North America, DTC is the most common endocrine malignancy accounting for 1% of all tumours ([Parker *et al*, 1997](#bib24){ref-type="other"}). Periodic radioiodine scanning and serum thyroglobulin (Tg) measurement are an integral part of the postoperative care. However, in about 13% of a population, interfering anti-Tg antibodies are present ([Pedersen *et al*, 2003](#bib25){ref-type="other"}) which may lead to a decreased Tg immunoassay sensitivity ([Ringel *et al*, 1998](#bib27){ref-type="other"}; [Spencer *et al*, 1998](#bib30){ref-type="other"}). Additionally, appropriate serum Tg measurement requires a TSH stimulus achieved by rhTSH administration, which obviates the need for long-term thyroid hormone withdrawal, leading to patient morbidity due to symptomatic hypothyroidism. Both concepts may cause tumour growth stimulation. Despite improved therapy concepts and excellent prognosis, tumour relapse and metastases do occur in 10% of patients ([Mazzaferri, 2000](#bib22){ref-type="other"}). Thus, over the last decade, many studies have attempted to improve DTC diagnosis and patient follow-up using RT--PCR-based approaches in order to track down circulating tumour cells ([Ditkoff *et al*, 1996](#bib10){ref-type="other"}; [Tallini *et al*, 1998](#bib35){ref-type="other"}; [Ringel *et al*, 1999](#bib26){ref-type="other"}; [Wingo *et al*, 1999](#bib39){ref-type="other"}; [Biscolla *et al*, 2000](#bib1){ref-type="other"}; [Bojunga *et al*, 2000](#bib2){ref-type="other"}; [Weber *et al*, 2000](#bib38){ref-type="other"}; [Bugalho *et al*, 2001](#bib3){ref-type="other"}; [Takano *et al*, 2001](#bib34){ref-type="other"}; [Eszlinger *et al*, 2002](#bib13){ref-type="other"}; [Span *et al*, 2003](#bib29){ref-type="other"}; [Chinnappa *et al*, 2004](#bib7){ref-type="other"}; [Elisei *et al*, 2004](#bib11){ref-type="other"}; [Li *et al*, 2004](#bib19){ref-type="other"}).

Thyroglobulin mRNA was thought to originate from circulating thyrocytes ([Ringel *et al*, 1998](#bib27){ref-type="other"}), but other studies demonstrated that physiological blood cells such as leukocytes are capable of ectopic Tg mRNA transcription ([Tallini *et al*, 1998](#bib35){ref-type="other"}; [Bojunga *et al*, 2000](#bib2){ref-type="other"}; [Bugalho *et al*, 2001](#bib3){ref-type="other"}; [Takano *et al*, 2001](#bib34){ref-type="other"}; [Eszlinger *et al*, 2002](#bib13){ref-type="other"}). To overcome these inherent limitations, one must consider either cumbersome tumour cell enrichment from peripheral blood or amplification of tumour-specific markers. However, the exact origin of Tg transcripts in healthy volunteers remains to be elucidated, and molecular approaches should integrate sequences lacking the phenomenon of illegitimate transcription in order to obtain signals specific for the respective malignant cell.

In order to monitor patients with DTC for minimal residual disease by blood assays, we decided to analyse promising candidate transcripts, which have been discussed to be useful in this context. For instance, cytokeratin 19 (CK 19) transcripts were used in several studies as a molecular marker for tumour cell detection ([Datta *et al*, 1994](#bib8){ref-type="other"}; [Burchill *et al*, 1995](#bib4){ref-type="other"}; [Eltahir *et al*, 1998](#bib12){ref-type="other"}; [Trummer *et al*, 2000](#bib36){ref-type="other"}).

Furthermore, human telomerase reverse transcriptase (hTERT) activity is associated with the majority of malignancies, and its activity is absent in most benign tissues ([Kim *et al*, 1994](#bib18){ref-type="other"}; [de Kok *et al*, 1999](#bib9){ref-type="other"}; [Holt and Shay, 1999](#bib17){ref-type="other"}; [Soria *et al*, 1999](#bib28){ref-type="other"}).

During tumorigenesis, fibronectin is alternatively spliced, leading to isoforms such as the extracellular domains A/B (ED-A/ED-B) and the III-connecting segment (III-cs) ([Takano *et al*, 1997](#bib32){ref-type="other"}, [1999](#bib31){ref-type="other"}, [2000](#bib33){ref-type="other"}). These uniquely glycosylated isoforms are predominantly expressed by foetal and neoplastic cells, and have been designated oncofoetal fibronectin (onfFN) ([Guller *et al*, 2003](#bib16){ref-type="other"}).

The overall purpose of this study is to analyse the expression of Tg, thyroid-stimulating hormone receptor (TSH-R), CK 19, hTERT, and onfFN transcripts in leukocytes, as well as in papillary thyroid carcinomas (PTCs) and follicular thyroid carcinomas (FTCs), respectively. Conspicuous mRNA sequence abundance in DTC combined with unequivocal absence in leukocytes will serve as a valuable diagnostic tool in cancer cell detection in the peripheral blood, which is finally tested in a small group of patients. Herein, we intentionally confine our focus to a selected number of mRNA transcripts which can be useful in future investigations of minimal residual disease in DTC with promising clinical applications.

MATERIALS AND METHODS
=====================

Patient samples and blood
-------------------------

The local university ethics committee approved the study and informed consent was obtained from all patients. Tissue samples from patients suffering from FTC or PTC and from nonmalignant thyroid glands were collected intraoperatively (FTC: *n*=18, PTC: *n*=48, nonmalignant thyroid=4), immediately snap-frozen in liquid nitrogen, and stored at −80°C. Of the FTC group, five tumours represented oxyphilic thyroid carcinomas displaying follicular architecture in more than 30% of the tumour ([Musholt *et al*, 2003](#bib23){ref-type="other"}). The diagnosis of all thyroid tissues was histopathologically confirmed by an experienced pathologist prior to analysis.

Commercial cDNA from different leukocyte fractions was used as template for PCR (MTC Panel, Clontech, Heidelberg, Germany).

Two individuals with a history of medullary thyroid carcinoma (MTC=C-cell carcinoma) who additionally underwent radio-iodine treatment following total thyroidectomy served as negative controls for thyrocyte-depleted human blood. For onfFN expression analysis, blood samples from nine patients suffering from either FTC or PTC metastatic disease and from eight healthy control individuals were obtained. Mononuclear peripheral blood cells were isolated from 5 ml EDTA treated blood by Ficoll-Paque® (Nycomed, Oslo, Norway) density gradient centrifugation according to the manufacturer\'s protocol.

RNA extraction
--------------

Total RNA was extracted from tissue samples (20 mg) by TRIzol Reagent (Invitrogen, Karlsruhe, Germany), and genomic DNA was eliminated by DNase I digest (Roche Diagnostics, Mannheim, Germany) prior to RNA purification (RNeasy Kit, Qiagen, Hilden, Germany). Peripheral blood-derived total RNA was isolated using only the column-based RNeasy Kit (Qiagen). The total RNA concentration was measured fluorometrically by use of RiboGreen RNA Quantitation Kit (MoBiTec, Goettingen, Germany).

RT--PCR
-------

Synthesis of cDNA was performed using either 4 *μ*g (tissue samples) or 1 *μ*g (blood samples) of total RNA and 3 *μ*l oligo-dT~20~ primer (25 pmol *μ*l^−1^) (MWG, Ebersberg, Germany). Following incubation at 70°C for 10 min, a reaction mixture containing 4 *μ*l dNTPs (5 mmol *μ*l^−1^ of each dNTP) (Roche Diagnostics), 8 *μ*l 5 × SuperScript II Buffer, 4 *μ*l DTT (0.1 mmol *μ*l^−1^) and 1 *μ*l SuperScript II (200 U *μ*l^−1^) (Invitrogen) was added and then incubated for another 50/10 min at 42/70°C. The final volume of this mixture was adjusted to 100 *μ*l using tRNA solution (0.25 mg ml^−1^) (Roche Diagnostics). For the PCR reaction, 9.5 *μ*l of diethyl pyrocarbonate (DEPC)-treated double-distilled H~2~O (ddH~2~O) was added to 2.5 *μ*l of cDNA. Amplification was performed in 25 *μ*l total volume containing 2.5 *μ*l 10 × reaction buffer (Promega, Mannheim, Germany), 1.5 *μ*l MgCl~2~ (25 mmol *μ*l^−1^), 0.4 *μ*l Taq polymerase (5 U *μ*l^−1^) (Qiagen), 1 *μ*l DTT (25 mmol *μ*l^−1^), 0.5 *μ*l of each oligonucleotide (50 pmol *μ*l^−1^) (MWG), 1 *μ*l dNTPs (5 mmol *μ*l^−1^) (Roche Diagnostics) and 13 *μ*l DEPC-ddH~2~O. After incubation at 94°C for 3 min, a touch-down PCR programme was started at 94°C/annealing temperature +10/72°C for 30/45/60 s with increments of 1°C each for two cycles, followed by 15 cycles at the specific annealing temperature and an incubation at 70°C for 5 min. Reaction mixtures either lacking template or containing RNA instead of cDNA served as negative controls. The primer sequences and annealing temperatures used in this study are listed in [Table 1](#tbl1){ref-type="table"}.

Polyacrylamide (15%) gel electrophoresis (PAGE)
-----------------------------------------------

Vertical PAGE was used for PCR product separation, and the amplicons were visualised by silver staining as described previously ([Lichtinghagen *et al*, 1994](#bib20){ref-type="other"}). Resulting signals were subdivided semiquantitatively in the categories high, intermediate, low and none according to their band intensities.

Real-time PCR
-------------

Fluorescence resonance energy transfer (FRET) technology (LightCycler, Roche Diagnostics) was used for real-time PCR analysis. Expression of the low-abundance housekeeping gene PBGD served as an internal positive control in each assay performed. A reaction mixture contained 2.5 *μ*l cDNA, 2 *μ*l PBGD/onfFN primer (10 pmol *μ*l^−1^) (see [Table 1](#tbl1){ref-type="table"}), 2 *μ*l FRET probes (4 pmol *μ*l^−1^) PBGD-FITC (tcctcctggcttcaccatcggagc-FITC), PBGD Cy5.5 (Cy5.5-tctgcaagcgggaaaaccctcatg), onfFN-IIICS-FITC (ggtatgacactggaaatggtattcagct-FITC), onfFN-IIICS- Cy5.5 (Cy5.5-tggcacttctggtcagcaacccag) (MWG), 2 *μ*l Fast Start DNA Master Hybridization Mix, 3.2 *μ*l MgCl~2~ (25 mmol l^−1^) and 1 *μ*l DMSO (Roche Diagnostics). The mixture was adjusted to 20 *μ*l using DEPC-ddH~2~O. For denaturation, a temperature of 95°C was maintained for 12 min. Amplification was performed at 95/59/72°C for 15/12/10 s (PBGD: 50 cycles, onfFN: 38 cycles, slope: 20°C s^−1^) without colour compensation mode. A standard calibration curve was constructed for each sequence after cloning of positive controls as described previously ([Lichtinghagen *et al*, 1995](#bib21){ref-type="other"}), and the assay sensitivity was determined using dilutions of the positive controls. Reaction mixtures either lacking template or containing RNA served as negative controls. In order to determine the real-time PCR sensitivity, an absolute quantification of PBGD and onfFN target sequences was calibrated by use of cloned cDNA serial dilutions. The standard curve started at 10^8^ (onfFN)/10^7^ (PBGD) initial cDNA copies. After measurement of the relative fluorescence intensity (channel F3/F1) for each sample, a proportional baseline adjustment for sample quantification was carried out by second derivative maximum calculation, and the amount of each mRNA transcript was expressed as a threshold cycle (ct) value.

Resulting ct values were used for statistical analysis to determine the significant differences of onfFN and PBGD mRNA expression in PTCs and FTCs, respectively, using a two-sample *t*-test.

RESULTS
=======

Illegitimate transcription of supposedly thyrocyte-specific transcripts in leukocytes
-------------------------------------------------------------------------------------

Activated and resting leukocyte subgroups were analysed for transcription patterns of thyroid-associated mRNA products by RT--PCR analysis. Whereas each leukocyte subgroup tested positive for transcripts of Tg, TSH-R, and PBGD, divergent expression profiles of hTERT, CK 19, and onfFN were observed in CD subgroups.

hTERT transcripts were not detected within resting CD4^+^ cells and were found at only low levels within the CD8^+^ population. Resting CD14^+^ cells as well as activated and resting CD19^+^ cells lacked CK 19 transcripts. All other fractions expressed CK 19. The weakest expression was demonstrated in the CD8^+^ group. No leukocyte subgroup tested transcribed onfFN mRNA ([Figure 1](#fig1){ref-type="fig"}).

Nucleated peripheral blood cells of two patients without any residual thyroid tissue following treatment for medullary thyroid carcinoma were positive for Tg mRNA ([Figure 2](#fig2){ref-type="fig"}).

Tissue samples
--------------

Total RNA was extracted from 48 PTCs, 13 FTCs, and five oxyphilic follicular thyroid carcinomas (oxyFTCs) -- often synonymously designated as Huerthle cell carcinomas -- and four nonmalignant thyroid tissue samples. RT--PCR for PBGD, hTERT, onfFN, and CK 19 was performed and analysed by PAGE. As expected, PBGD expression was detectable in all tumours examined. Half of the FTC samples and 29% of the PTC tumours were negative for hTERT. High levels of hTERT were observed in 34/33% (FTC/PTC), intermediate levels in 6/31%, and a low level of expression occurred in 11% of each tumour group. Detectable levels of onfFN transcripts were present in 78/98% (FTC/PTC). The FTC samples revealed high expression in 11% of the tumours, whereas a high expression of onfFN was observed in 60% of PTCs. Intermediate and low levels (17%) of onfFN were detected in one-half of the FTC samples. A quarter of all PTC tumours displayed intermediate and low (13%) onfFN signals. All tumour tissues transcribed CK 19 at a relatively high level (66% for FTCs; 88% for PTCs). Intermediate and low levels were measured in 17% of FTCs and 6% of PTCs examined ([Figure 3](#fig3){ref-type="fig"}). There was no specific expression pattern detectable discerning oxyFTCs from FTCs without oxyphilic histomorphology. Nonmalignant thyroid tissue samples were only analysed for onfFN mRNA expression and were found to be negative.

Quantification
--------------

In order to determine the real-time PCR sensitivity, an absolute quantification of PBGD and onfFN target sequences was calibrated by use of cloned cDNA serial dilutions. Sensitivity of the assay was determined to be 10^3^ (onfFN)/10^4^ (PBGD) cDNA molecules per reaction. The correlation coefficient was *R*=0.99 for onfFN as well as for PBGD.

In order to determine the inter-assay precision, two samples of both onfFN and PBGD standards of different concentrations were cycled eight times in a row. Amplification of 10^6^ cDNA copies (onfFN and PBGD) revealed a mean ct value of 19.75 (s.d.±0.16, CV=0.8%) for onfFN, and 22.08 (s.d.±0.56, CV=9.2%) for PBGD, respectively. Amplification of a lower concentration (onfFN: 10^3^, PBGD: 10^5^) proved a mean ct value of 25.84 (s.d.±2.39, CV=9.2%) for onfFN and 24.9 (s.d.±0.22, CV=0.9%) for PBGD.

PBGD and onfFN transcripts of 18 FTC and 48 PTC samples were then quantified by real-time PCR using the calibration curve made of diluted cloned controls. Calculation was performed by second derivative maximum analysis and the quantity of each transcript was expressed as ct values. A mean PBGD ct was observed at 25.95±0.73 for FTC samples and 24.55±5.43 for PTC tumours, demonstrating no significant difference (*P*=0.2878). onfFN ct were calculated at 25.48±3.15 and 21.44±3.44 for FTC and PTC samples, respectively. The expression difference between both tumour groups was significant (^\*^*P*=0.0001) ([Figure 4](#fig4){ref-type="fig"}).

Peripheral blood from patients with confirmed FTC or PTC metastases tested positive for onfFN mRNA expression in six out of nine cases using the established assay. The signal was significantly (^\*^*P*=0.015) higher in patients (mean: 1.7 × 10^4^, s.d.: 8.6 × 10^3^ (arbitrary units)) compared to controls (*n*=8) (mean: 7.1 × 10^3^, s.d.: 2.0 × 10^3^ (arbitrary units)). A cutoff value (3 × s.d.+mean=1.3 × 10^4^ (arbitrary units)) was applied to identify positive samples ([Figure 5](#fig5){ref-type="fig"}). The results were confirmed three times with a high reproducibility.

Using a thyroid carcinoma cell line dilution model, we found one tumour cell in 10^6^ mononuclear cells (data not shown).

DISCUSSION
==========

In the recent past years, a considerable number of papers reporting tissue-specific or cell-specific gene expression analyses for diagnosis of minimal residual disease in DTCs following total thyroidectomy were published. Some laboratories focused on Tg mRNA as a thyroid-associated gene product in detecting DTC cells in peripheral blood; however, Tg expression analysis produced ambiguous and diverse results ([Ditkoff *et al*, 1996](#bib10){ref-type="other"}; [Tallini *et al*, 1998](#bib35){ref-type="other"}; [Ringel *et al*, 1999](#bib26){ref-type="other"}; [Wingo *et al*, 1999](#bib39){ref-type="other"}; [Bojunga *et al*, 2000](#bib2){ref-type="other"}; [Bugalho *et al*, 2001](#bib3){ref-type="other"}; [Takano *et al*, 2001](#bib34){ref-type="other"}; [Eszlinger *et al*, 2002](#bib13){ref-type="other"}; [Grammatopoulos *et al*, 2003](#bib15){ref-type="other"}). A recently published review concluded that Tg mRNA measurement is an invalid approach in the postoperative care of patients with DTC due to illegitimate expression of this marker in peripheral blood cells, although RT--PCR concepts in general are worthy of further investigations ([Verburg *et al*, 2004](#bib37){ref-type="other"}). However, two other studies demonstrated results opposite to the conclusions drawn in this review, and reported a high specificity of Tg or TSH-R mRNA for thyroid cancer, hence promoting their application in DTC detection ([Chinnappa *et al*, 2004](#bib7){ref-type="other"}; [Li *et al*, 2004](#bib19){ref-type="other"}). Therefore, the experimental usefulness of Tg transcripts and the potential clinical relevance of this marker are still under debate.

A somewhat different method capable of detecting circulating thyroid carcinoma cells was first described by [Ditkoff *et al* (1996)](#bib10){ref-type="other"}. In their study, Tg mRNA was present in the peripheral blood of all patients with metastatic cancer, but absent in controls and in almost all individuals in disease remission. Investigators subsequently interpreted their observations to be correlated with extrathyroidal disease. Others reported a previously Tg mRNA negative control group revealing positive results following extended PCR amplification. The same was true for 10 human cell lines tested ([Tallini *et al*, 1998](#bib35){ref-type="other"}). Healthy individuals who revealed circulating Tg mRNA transcripts in the peripheral blood were also described by [Ringel *et al* (1998)](#bib27){ref-type="other"} using the RT--PCR technique. They interpreted their findings with a putative pool of circulating normal thyrocytes which produced Tg mRNA.

Refuting, we studied the peripheral blood of two patients lacking any residual thyroid tissue whatsoever because they underwent not only thyroidectomy for medullary thyroid carcinoma (originating from intrathyroidal C-cells and not from thyrocytes) but also -- as an unusual additional treatment -- radio-iodine therapy after surgery. The leukocyte fraction of these two individuals separated by density gradient centrifugation notedly revealed Tg mRNA expression ([Figure 2](#fig2){ref-type="fig"}). In addition, we have clearly demonstrated an ectopic transcription of Tg and TSH-R mRNA in all nucleated cell fractions of the peripheral blood using a highly sensitive two-step RT--PCR method ([Figure 1](#fig1){ref-type="fig"}). These findings strongly support the hypothesis that lymphocytes, monocytes and granulocytes express markers illegitimately, which were reported to be thyrocyte-specific. This phenomenon leads to a significant thyrocyte-independent PCR background signal, which interferes with assays using Tg and TSH-R mRNA. Based on these data, one can conclude that the hypothesis of circulating thyrocytes in healthy individuals as the source of peripheral Tg transcripts proposed by Ringel *et al* is improbable ([Bojunga *et al*, 2000](#bib2){ref-type="other"}; [Bugalho *et al*, 2001](#bib3){ref-type="other"}; [Takano *et al*, 2001](#bib34){ref-type="other"}; [Eszlinger *et al*, 2002](#bib13){ref-type="other"}). Experimental trials or future clinical applications dealing with Tg or TSH-R mRNA transcripts should be wary of false-positive results. [Chelly *et al* (1989)](#bib5){ref-type="other"} reported that illegitimate transcription corresponds with a low expression level of spliced transcripts from specific genes in cells that are nonspecific for these transcripts. Due to identical promoter elements in specific and nonspecific cells, illegitimate or ectopic transcription is likely to be a result of a low promoter activity leading to nontranslated transcripts. The significance and widespread appearance of this phenomenon still need to be elucidated. A general tolerance of low-level promoter activity might be energetically advantageous for cellular metabolism rather than resting at complete promoter quiescence ([Chelly *et al*, 1991](#bib6){ref-type="other"}).

Concluding, in detection of minimal residual disease in DTC, either time-consuming, sophisticated carcinoma cell harvesting or detection of circulating cancer cell via nonillegitimately transcribed sequences is feasible. In our opinion, the latter approach is preferable because it is more sensitive, specific, cost-effective and subject to routine laboratory automation.

As long as no thyrocyte-specific master genes are available, the amplification of minor genes not primarily involved in thyroid function but abnormally expressed in certain stages of tumorigenesis -- due to gene deregulation and disturbances in molecular networks -- is currently the only approach for detection of minimal residual disease in thyroid carcinoma.

In order to establish a single marker-based tumour cell detection assay, a consistently high expression of the chosen target mRNA sequence by the malignant tissue is required. Thus, we studied expression rates of the potential target sequences hTERT, CK 19, and onfFN in PTCs, FTCs, nonmalignant thyroid tissue, as well as in leukocyte subgroups. Our results demonstrate the complete absence of onfFN transcripts in each CD population associated with a high expression rate in DTC samples ([Figures 1](#fig1){ref-type="fig"} and [3](#fig3){ref-type="fig"}), suggesting that the onfFN transcript is a useful target sequence for thyroid carcinoma cell detection within the peripheral blood. Additionally, a significant difference in onfFN mRNA expression between PTCs and FTCs was shown ([Figure 4](#fig4){ref-type="fig"}), whereas the nonmalignant thyroid tissue samples lacked onfFN transcripts (data not shown). In further support of our results, [Giannini *et al* (2003)](#bib14){ref-type="other"} assessed onfFN and galectin-3 mRNA in thyroid malignancies, and reported onfFN mRNA transcripts in almost 98% of PTCs.

Importantly, the analysis of peripheral blood from patients with known DTC metastatic disease revealed an onfFN mRNA expression in six out of nine patients identified by a well-defined cutoff value ([Figure 5](#fig5){ref-type="fig"}). This finding indicates the technical feasibility, reliability and potential clinical utility of this approach.

In summary, we have developed and optimised a specific, sensitive real-time RT--PCR assay using FRET technology in order to quantify absolute amounts of onfFN templates. A high expression rate of onfFN transcripts in DTCs was demonstrated, while onfFN mRNA was not found to be illegitimately transcribed by peripheral blood cells, but patients with DTC metastatic disease could be identified. These results may lead to a specific tool for monitoring micrometastases in the context of minimal residual disease or for assessing tumour response to therapy. The assay of onfFN-specific transcripts is a promising approach and worthy of further assessment in clinical trials.
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![Tg, TSH-R, the low-abundance house-keeping gene PBGD, hTERT, CK 19, and onfFN mRNA transcripts were PCR-amplified using cDNA from different leukocyte subgroups. Amplicons were visualised by PAGE, followed by silver staining. The subscripts (r and a) indicate resting or activated status, respectively, for each subgroup.](93-6602741f1){#fig1}

![In the study of minimal residual disease in DTC, two thyrocyte-depleted individuals -- suffering from medullary thyroid carcinoma and treated with thyroidectomy as well as with radio-iodine therapy -- served as negative controls [(]{.ul}MTC patients 1 and 2). RT--PCR amplification for Tg (lanes 1+3, product size: 405 bp) and PBGD (lanes 2+4, product size: 253 bp) transcripts was carried out following harvest of nucleated peripheral blood cells by density gradient centrifugation (M=100 bp DNA ladder). A notable expression of the supposedly thyrocyte-specific Tg is shown (PAGE, silver staining).](93-6602741f2){#fig2}

![Tissue samples of 18 FTCs and 48 PTCs were subjected to RT--PCR-based semiquantitative expression analysis for PBGD, hTERT, onfFN, and CK 19, respectively. Following PAGE and silver staining, band intensities were estimated and illustrated.](93-6602741f3){#fig3}

![Results of a real-time PCR quantification of PBGD and onfFN transcripts performed on cDNA from 18 FTC and 48 PTC samples are given using ct values after second derivative maximum analysis.](93-6602741f4){#fig4}

![Quantitative real-time PCR data are shown in a box plot graph. Based on an unspecific background signal obtained in healthy controls (*n*=8), we calculated a cutoff value (3 × s.d.+mean). onfFN transcripts were detected in the peripheral blood in 67% of patients (*n*=9) suffering from DTC metastatic disease. Expression rates of both groups are presented in arbitrary units based on copy numbers of a recombinant onfFN standard, leading to a better inter-assay precision in daily routine diagnostic.](93-6602741f5){#fig5}

###### 

Synopsis of the oligonucleotides used

  **Sense primer**   **Sequence**                 **Antisense primer**   **Sequence**                      ***T* (°C)**  **Bp**
  ------------------ ---------------------------- ---------------------- -------------------------------- -------------- --------
  PBGD-for           5′-attgctatgtccaccacagg-3′   PBGD-rev               5′-gcagggtttctagggtcttc-3′             59       253
  Tg-for             5′-gccctctcttcagtggttgt-3′   Tg-rev                 5′-ggaactccaaggaactggtc-3′             59       405
  TSH-R-for          5′-tggggacagtgaagacatgg-3′   TSH-R-rev              5′-tgaagaaaccagccgtgttg-3′             58       332
  CK19-for           5′-cagcattcacgggggctcc-3′    CK19-rev               5′-agcctgttccgtctcaaacttggt-3′         64       421
  hTERT-for          5′-tgaacttgcggaagacagtg-3′   hTERT-rev              5′-gaggctgttcacctgcaaat-3′             57       290
  onfFN-for          5′-tcttcatggaccagagatct-3′   onfFN-rev              5′-tatggtcttggcctatgcct-3′             56       215
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